Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Executive Summary
Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13
You may also be interested in...
NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer
Pfizer’s long-term safety outcome study comparing Celebrex, ibuprofen and naproxen has its flaws, but FDA advisory committee says its data will be far superior to meta-analyses or observational studies.
NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer
Pfizer’s long-term safety outcome study comparing Celebrex, ibuprofen and naproxen has its flaws, but FDA advisory committee says its data will be far superior to meta-analyses or observational studies.
NSAID Panel Could Give Naproxen Labeling Edge
FDA’s Arthritis and Drug Safety and Risk Management advisory committees on Feb. 10-11 will examine cardiovascular risk data for non-steroidal anti-inflammatory drugs, including meta-analyses indicating naproxen could have a better safety profile than other OTC ingredients ibuprofen and ketoprofen.